Sequential Release of mRNA Complex and T Cells by a Double-Layered Implantable Scaffold for Combination Therapy of Head and Neck Squamous Cell Carcinoma
Open Access
- 1 March 2026
- journal article
- research article
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-27
Abstract
Background: Head and neck squamous cell carcinoma (HNSCC) is associated with considerable morbidity and mortality, necessitating the development of novel therapeutic strategies. Adoptive cell therapy (ACT) and gene therapy are validated strategies for HNSCC treatment; however, both strategies have limitations when used alone in HNSCC and their synergistic integration requires further exploration to establish effective delivery platforms. In this study, we designed a double-layered scaffold based on photocurable hydrogel to combine mRNA gene therapy and ACT. And we aimed to validate the potential of this co-delivery scaffold in HNSCC treatment. Methods: An implantable, double-layered, spherical scaffold was designed using a photocurable hydrogel gelatin methacryloyl (GelMA) with suitable mechanical strength and compressive properties. This scaffold incorporated primary T cells derived from mouse lymph nodes within the inner layer and a DOTAP-mPEG-PCL (DMP)/mBim mRNA-based gene therapy complex within the outer layer. Characteristics of the scaffold and delivery capacity of DMP nanoparticles were first measured. Then the active functions of both therapeutic components were tested separately. The synergistic therapeutic efficacy of the scaffold was further validated using mouse subcutaneous and mandibular invasion models. The immune activation and killing processes associated with sequential release were measured in this process. Results: A double-layered spherical scaffold was produced and the DMP-mBim complex was characterized. The proliferation-inhibiting effect of the gene therapy complex on HNSCC cells was first demonstrated in vitro upon release, and the maintenance of T-cell bioactivity was confirmed. Results revealed the release process of two components during degradation of scaffold. The initially released DMP-mBim complex could induce immunogenic tumor cell death. Subsequently, tumor antigens generated during this process migrated into the scaffold along with the recruited dendritic cells (DCs). Activated T cells within the inner layer subsequently exerted tumor-killing effects after release. In HNSCC subcutaneous tumor and mandibular invasion models, local implantation of the double-layered scaffold effectively harnessed the synergistic effects of gene and cell therapies, inhibiting tumor growth and progression. Conclusion: The combination of DMP-mBim gene complex and T-cell therapies represents an effective immunotherapeutic strategy, and the sequential release of mRNA gene therapy and T cells within a double-layered hydrogel prolongs antitumor efficacy. This strategy presents a potential immunotherapeutic approach for HNSCC that warrants further validation to support its future clinical translation. Plain Language Summary: In this study, we developed an implantable spherical double-layered scaffold based on a photocurable GelMA hydrogel to combine gene and ACT. In this system, DMP-mBim gene therapy complexes are present in the outer layer, and primary T cells are present in the inner layer. Implantable scaffolds were implanted adjacent to a HNSCC mouse tumor model to perform immunogene therapy. After implantation, the outer layer was first released to exert a direct tumor-killing effect, inducing tumor cell apoptosis and antigen release. The subsequent release of activated T cells sustains an antitumor immune response. The therapeutic effects were confirmed in HNSCC subcutaneous xenograft and mandibular invasion models. This design provides a potential strategy for combined immunotherapy for the treatment of HNSCC.Keywords
This publication has 72 references indexed in Scilit:
- Metabolic reprogramming by chemo-gene co-delivery nanoparticles for chemo-immunotherapy in head and neck squamous cell carcinomaActa Biomaterialia, 2025
- Synergistic Chemoimmunotherapy Augmentation via Sequential Nanocomposite Hydrogel‐Mediated Reprogramming of Cancer‐Associated Fibroblasts in OsteosarcomaAdvanced Materials, 2023
- A Physiologically Responsive Nanocomposite Hydrogel for Treatment of Head and Neck Squamous Cell Carcinoma via Proteolysis‐Targeting Chimeras Enhanced ImmunotherapyAdvanced Materials, 2023
- Time-Programmed Delivery of Sorafenib and Anti-CD47 Antibody via a Double-Layer-Gel Matrix for Postsurgical Treatment of Breast CancerNano-Micro Letters, 2021
- Formulation and Delivery Technologies for mRNA Vaccines2020
- Photobiomodulation effects on head and neck squamous cell carcinoma (HNSCC) in an orthotopic animal modelSupportive Care in Cancer, 2019
- Co‐Delivery of Drugs and Genes Using Polymeric Nanoparticles for Synergistic Cancer Therapeutic EffectsAdvanced Healthcare Materials, 2017
- Clinical Evaluation of ErbB-Targeted CAR T-Cells, Following Intracavity Delivery in Patients with ErbB-Expressing Solid Tumors2015
- Selective inhibition of NF‐κB suppresses bone invasion by oral squamous cell carcinoma in vivoInternational Journal of Cancer, 2012
- Combination Nonviral Interleukin 2 Gene Therapy and External-Beam Radiation Therapy for Head and Neck CancerJAMA Otolaryngology–Head & Neck Surgery, 2003